Cryoport Third Quarter 2026 Earnings Call - CRYOPORT INC

Financial Performance:

• Q3 2026 total revenue reached $50.2 million, reflecting a 14% year-over-year increase.
• Life Sciences Services segment grew 18% to represent 57% of total revenue; commercial cell and gene therapy revenue specifically surged 20%.
• MVE products segment grew 8% driven by animal health demand and the Fusion line of cryogenic freezers.
• Company achieved positive adjusted EBITDA of $1.1 million for the quarter, marking the second consecutive quarter of profitability and a $1.8 million year-over-year improvement.
• Long-term margin targets remain unchanged: 55% gross margins and 30% adjusted EBITDA margins.
• Revenue guidance for full-year 2026 raised to $197 million–$199 million (midpoint $198M), implying 12% YoY growth.

Guidance and Future Outlook:

• Full-year 2026 outlook increased based on strong Q1–Q3 performance and increased visibility in the pipeline.
• Q4 2026 implied revenue guidance is approximately $50 million–$52 million.
• Management expects further operating leverage and EBITDA margin expansion in 2027 and beyond as global capacity utilization increases.
• Pipeline outlook includes five additional BLA/MAA filings and two potential new therapy approvals (one in November, one in December) in Q4; previously projected 2026 approvals for three therapies have been pushed to 2027.
• Long-term market growth for cell and gene therapies is projected at a 34% CAGR (2025–2031) by the Alliance for Regenerative Medicine, reaching ~$60 billion.
• Two new facilities (Paris, France; Santa Ana, California) adding bioservice capabilities are expected to be fully operational by 2027.
• IntegraCell cryopreservation network is expanding to Morris Plains in 2027 to support client diversification.

Business Segments and Product Lines:

• Life Sciences Services: Core growth driver; supporting 23 commercial therapies; clinical trial pipeline reached a record 788 (up 43 YoY), with 99 in Phase 3.
• Cell and Gene Therapy: Strong momentum in commercial shipments (20% growth) and Phase 3 program acceleration due to increased funding and biotech consolidation.
• MVE (Products): Market leader in cryogenic systems; robust performance in animal health (bovine reproduction) and protein production demand.
• Bioservices: Growing at >20% YoY; includes sterile kitting (launched in Belgium, expanding to Houston in 2027), allogeneic therapy fulfillment, and biostorage.
• New Offerings: CryoGene launched a new Cryogenic Technical Services (CTS) division to meet client demand in Texas; global supply chain centers in Paris and Santa Ana now offer full integrated bioservices platforms.
• IntegraCell: Early-stage commercialization with consistent patient counts in Houston and Belgium; aiming to become a standard for community care cryopreservation.

Market and Competitive Landscape:

• Cryoport maintains a leadership position in the cell and gene therapy ecosystem with an integrated end-to-end platform.
• Gained ISO 9001 and ISO 21973 certifications (the latter a new international standard for cell transportation risk), earning the 2026 Supply Chain Excellence USA Award.
• Market consolidation (e.g., Gilead acquiring Arcelix) is driving demand for rapid launch and scaling capabilities.
• China operations remain stable (3–4% of total revenue), serving as an internal component supplier and external exporter for animal health.
• Replimune received accelerated FDA approval for a melanoma treatment, adding to the 23 supported commercial therapies.

Risks and Challenges:

• Pipeline Timing Risks: Regulatory approval dates (PDUFA) may shift between years (e.g., three 2026 approvals moved to 2027).
• New Facility Margins: Initial ramp-up of new bioservice centers in Paris and Santa Ana may temporarily impact gross margins before efficiencies are realized.
• External Factors: Macroeconomic conditions and government-related uncertainties remain embedded in the conservative Q4 guidance stance.
• Cyclical Markets: Animal health demand is cyclical, though currently experiencing a surge in protein production needs.

Management Commentary and Tone:

• Tone is highly confident and bullish, emphasizing "fantastic momentum" and a "bright future."
• Management highlights the "Pathway to Profitability" initiative as a key success, citing disciplined execution and operating leverage.
• CEO noted the broad-based strength across both services and products, with commercial therapy activity driving the majority of growth.
• CFO and CEO emphasized the importance of quality and validation while building global capacity, expecting significant operating leverage in 2027.

Analyst Questions and Answers:

• Guidance Drivers: Q4 guidance reflects broad-based strength rather than specific new approvals, which are not yet ramped.
• China Strategy: MBE China operations are stable; revenue is 3–4% of total but critical for supplying components to US facilities.
• Margin Cadence: Margins will see initial pressure from new facility ramp-up but are expected to climb with volume in 2027.
• MVE Revenue Drivers: Growth driven primarily by animal husbandry (bovine) and the new Fusion freezer line, with regional growth across Americas, Asia Pacific, and EMEA.
• Bio-services Long-term: Expected to remain a double-digit grower as clients seek integrated biostorage and processing solutions.
• 2027 Launches: Potential incremental revenue from Arcelix (Gilead) and a first-in-class autoimmune therapy approval in early 2027.
• IntegraCell: Strategy focuses on providing standardized cryopreservation competencies to expand community care access for clients lacking on-site infrastructure.
• CryoGene CTS: New service offering is a natural response to client demand in key Texas markets.

Other Key Points:

• Discontinued Operations: Financials for CryoPDP (sold to DHL in June 2025) are now reported as discontinued operations; all revenue guidance refers to continuing operations.
• Clinical Pipeline Health: 8 trials completed in Q3, indicating maturation of the pipeline and progression toward regulatory filings.
• Customer Diversification: Increased uptake of sterile kitting in Belgium and upcoming expansion to Houston.
• Global Capacity: Network expansion is designed to capture the anticipated 34% CAGR in the cell and gene therapy market through 2031.